Vaxcyte, Inc. (PCVX)
Nasdaq: PCVX · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2015
Filings
222 filings since 2017 beside 547 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 23, 2026.
Filings a yearinsider forms included
462971029919982122
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 7 times in the last 36 months, the newest Sep 3, 2026.SEC letters: 3 in the last 36 months, the newest May 14, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Oct 9, 2026
8-K items 1.01, 2.03, 8.01, 9.01
Major agreement signed; New debt or obligation taken on; Other event · Current report
Oct 6, 2026
Oct 5, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Sep 3, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Aug 31, 2026
40 of 222 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.